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Objective Women with ovarian cancer have poor survival rates, which have proven difficult to improve; 33 
therefore primary prevention is important. The levonorgestrel-releasing intrauterine system (LNG-IUS) 34 
prevents endometrial cancer, and recent studies suggested that it may also prevent ovarian cancer, but 35 
with a concurrent increased risk of breast cancer. We compared adjusted risks of ovarian, endometrial, 36 
and breast cancer in ever users and never users of LNG-IUS. 37 
Methods Our study cohort consisted of 104 318 women from the Norwegian Women and Cancer Study, 38 
9144 of whom were ever users and 95 174 of whom were never users of LNG-IUS. Exposure information 39 
was taken from self-administered questionnaires, and cancer cases were identified through linkage to 40 
the Cancer Registry of Norway. Relative risks (RRs) with 95% confidence intervals (CIs) were estimated 41 
with Poisson regression using robust error estimates(1). 42 
Results Median age at inclusion was 52 years and mean follow-up time was 12.5 (standard deviation 43 
3.7) years, for a total of 1 305 435 person-years. Among ever users of LNG-IUS there were 18 cases of 44 
epithelial ovarian cancer, 15 cases of endometrial cancer, and 297 cases of breast cancer. When ever 45 
users were compared to never users of LNG-IUS, the multivariable RR of ovarian, endometrial, and 46 
breast cancer was 0.53 (95% CI: 0.32, 0.88), 0.22 (0.13, 0.40), and 1.03 (0.91, 1.17), respectively.  47 
Conclusion In this population-based prospective cohort study, ever users of LNG-IUS had a strongly 48 
reduced risk of ovarian and endometrial cancer compared to never users, with no increased risk of 49 
breast cancer.  50 





In 2012, ovarian cancer caused an estimated 152 000 deaths worldwide (2). The cumulative risk of 54 
ovarian cancer until age 75 is 1.3% in Norway and is similar in the United States (3, 4). The symptoms of 55 
ovarian cancer are vague, and there is no screening test. This has led to problems of late diagnosis and a 56 
5-year survival of less than 50% (5). Thus, ovarian cancer ranks eighth in cancer incidence, but fifth in 57 
cancer mortality among women (4). Primary prevention therefore remains the best available measure 58 
against ovarian cancer (5).  59 
Risk of ovarian cancer is reduced by 15-29% for every 5 years of oral contraceptive (OC) use, and 60 
globally, OC use prevents an estimated 30 000 cases of ovarian cancer each year (6). Long-term OC use 61 
also reduces the risk of endometrial cancer, with 5-9 years of use reducing the risk by 34% (7). However, 62 
OC use increases the risk of breast cancer up to 38% with more than 10 years use, and for minimum 5 63 
years after cessation (8, 9) in addition to carrying other health risks. Prescribing OCs for ovarian cancer 64 
prevention to women who do not need contraception is not recommended (10).   65 
The levonorgestrel-releasing intrauterine system (LNG-IUS) was introduced in Norway in 1994. In 66 
the Nordic countries, LNG-IUS is the second-most used form of contraception after OCs, and it is the 67 
most commonly used form of long-acting reversible contraception (11). Recently, three Finnish studies 68 
have shown that, compared to the general population, LNG-IUS users have a standardized incidence 69 
ratio (SIR) of 0.59 for ovarian cancer and 0.46 for endometrial cancer (12, 13), but also an increased risk 70 
of ductal and lobular breast cancer (SIR 1.20 and 1.33 respectively, increasing to SIR 1.37 and 1.73 with 71 
more than 5 years of use) (14). However, these studies did not adjust for other hormonal risk factors.  72 
Our study aim was to combine self-reported information on OC use and reproductive factors from 73 
the Norwegian Women and Cancer (NOWAC) Study, with registry-based follow-up of cancer cases to 74 
compare adjusted risks of ovarian, endometrial, and breast cancer in ever users and never users of LNG-75 
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IUS. We also included estimates of the reduction in the risk of endometrial cancer in this nationally 76 
representative cohort, given the well-known preventive effect of LNG-IUS use on this cancer (15).  77 
METHODS 78 
Study cohort  79 
The NOWAC Study is a population-based prospective cohort study designed to investigate the 80 
association between hormone use and hormone-dependent female cancers (16). During 1991-2007, 81 
women born between 1927 and 1965 were randomly selected from the Norwegian Population Registry 82 
and were sent a questionnaire along with a letter that explained the study. Those who returned a 83 
completed questionnaire were enrolled. Statistics Norway replaced participants’ names and personal 84 
identification numbers with serial numbers for use by researchers. Recruitment took place in two waves: 85 
102 540 participants were enrolled in 1991-1997 (response rate 57%), and 63 232 participants in 2003-86 
2006 (response rate 48.4%). The external validity of the NOWAC Study was found to be good (17). 87 
Follow-up information has been collected up to two times after enrollment.  88 
The NOWAC questionnaires targeted LNG-IUS use as from 1998 by the question: Have you ever used 89 
a hormone intrauterine device? A total of 145 320 women completed a questionnaire during 1998-2006, 90 
either at enrollment or as part of follow-up. From these, we excluded 33 182 that either did not answer 91 
the question on hormone intrauterine device or had a hysterectomy or oophorectomy; 4813 that either 92 
had prevalent cancer or died or emigrated before the start of follow-up; 2938 that indicated LNG-IUS 93 
use before the device was available in Norway, and seven for technical reasons. Thus the final study 94 
cohort consisted of 104 380 women, of which 9146 were ever users of LNG-IUS.  95 
Exposure assessment 96 
In addition to questions on LNG-IUS (ever use, duration of use, age at first use, current use), we 97 
identified eight exposure variables associated with ovarian, endometrial, or breast cancer (18), 98 
regardless of their association with LNG-IUS use: age at start of follow-up (41-76 years, in 4-year 99 
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increments), body mass index at enrollment (BMI, <25 kg/m2, ≥25 kg/m2), physical activity level at 100 
enrollment (very low, low, intermediate, high, very high), maternal history of breast cancer (yes, no), 101 
age at menarche (<12, 12-14, ≥15), ever use of OCs (yes, no),  parity (0, 1-2, 3-4, ≥5), and menopausal 102 
status at start of follow-up (pre, peri, post, unknown). Unknown menopausal status was given to those 103 
who used hormone replacement therapy, those who indicated that menses had stopped due to 104 
“medication, illness, exercise, or other” and to those who did not answer the question.  105 
Outcomes 106 
Primary cancers were identified through linkage to the Cancer Registry of Norway using the 107 
International Classification of Diseases, Revision 7 (ICD-7) codes. All citizens were identified by their 108 
personal identification number upon contact with health care providers, who are obliged to report all 109 
cancer cases to the Cancer Registry of Norway. Cases were defined as cancer of the ovary including the 110 
fallopian tube (ICD-7 code 175), cancer of the uterine corpus (ICD-7 code 172), and cancer of the breast 111 
(ICD-7 code 170). In order to restrict the analyses to epithelial ovarian cancer and endometrial cancer, 112 
non-carcinoma cancers of the ovary and uterine corpus were excluded from the analyses (n=62). Deaths 113 
and emigrations were identified through the Cause of Death Registry and Statistics Norway. Follow-up 114 
ended on 31 December 2015. 115 
Statistical analysis 116 
We calculated person-years (PY) of follow-up from the date of entrance into, until the date of exit from 117 
the study. Exit date was defined as the date of cancer diagnosis, emigration from Norway, death, or end 118 
of follow-up, whichever occurred first. We used chi-squared tests of independence to compare the 119 
characteristics of ever users and never users of LNG-IUS, and to compare selected characteristics of 120 
responders and non-responders of the question on LNG-IUS use.  121 
We calculated crude cancer incidence rates with 95% confidence intervals (CIs) assuming a Poisson 122 
distribution. Relative risks (RRs) and their 95% CIs were estimated with Poisson regression using a robust 123 
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error estimate. Adjusted RR models were built in a stepwise backward manner by removing 124 
nonsignificant covariates from the full model, with listwise deletion of participants with missing 125 
information. Model fit was assessed by testing the deviance versus its assumed chi-squared distribution. 126 
Statistical significance was defined as a test resulting in a p-value <0.05. We performed an additional 127 
analysis of the association between LNG-IUS use and endometrial cancer, stratified by ever OC use (yes, 128 
no), and did a Wald test of heterogeneity between the resulting RRs. We performed two additional 129 
analyses of the association between LNG-IUS use and breast cancer: stratified by duration of use (≤5 and 130 
>5 years), and stratified into current and former users at the start of follow-up. 131 
The analyses were performed in SAS software version 9.4 (SAS Institute, Inc., Cary, NC, USA ).  132 
Ethics 133 
The Regional Ethics Committee, REK Nord, approved the NOWAC Study. Written information was 134 
provided to the participants, and return of a completed questionnaire was considered as consent to 135 
participate. Data storage is in compliance with the rules of the Norwegian Data Inspectorate. 136 




Median age at inclusion was 52 years. Mean follow-up time was 12.5 (standard deviation [SD] 3.7) years 139 
for a total of 1 305 435 PY. Among all ovarian and uterine corpus cancers, respectively 4% and 5% were 140 
non-carcinoma cancers and were excluded. Of the women in the study cohort, 9144 (9%) reported LNG-141 
IUS use during or prior to the data collection period (1998-2007). Among ever users of the LNG-IUS, 85% 142 
reported the duration of use. Median age at starting LNG-IUS use was 44 years, and median duration 143 
was 4 years, with 59% having used LNG-IUS for between 2 and 6 years. Compared to never users, ever 144 
users of LNG-IUS were younger at start of follow-up (Table 1).  145 
The percentage of women that reported high or very high physical activity level was slightly higher 146 
among ever users of LNG-IUS (38% versus 30% of never users) (Table 1). Ever use of OCs was more 147 
common among ever users of LNG-IUS (71%) than never users (55%), and nulliparity was more common 148 
among never users of LNG-IUS (10% vs. 3% among ever users). Menopausal status at start of follow-up 149 
was significantly different between the groups of LNG-IUS use, with 60% of never users reporting that 150 
they were postmenopausal, compared to 33% of ever users. Thirty percent (n=2753) of ever users had 151 
unknown menopausal status, and of these, 85% were using LNG-IUS at the start of follow-up.  152 
Non-responders to the LNG-IUS question (n=15442) differed significantly from the study cohort on 153 
all variables checked. Most notably they had a lower proportion of nullipara (Supplementary table S1). 154 
 155 
Levonorgestrel-releasing intrauterine system and cancer incidence 156 
Table 2 displays cancer incidences and risk estimates. The crude incidence rate of ovarian cancer among 157 
never users of LNG-IUS was 38.1 (95% CI: 34.7, 41.8). The crude incidence rate of ovarian cancer among 158 
ever users of LNG-IUS was 16.7 per 100 000 PY (95% CI: 9.9, 26.4), with an age-adjusted RR of 0.49 (95% 159 
CI: 0.30, 0.82) for ever versus never users. The final model for ovarian cancer included three significant 160 
covariates: age at start of follow-up, ever use of OCs, and menopausal status at start of follow-up. Parity 161 
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was not significant in the model building, but qualified as a confounder and was included in the model. 162 
Adjustment for these covariates hardly changed the risk estimates (multivariable-adjusted RR 0.53 (95% 163 
CI: 0.32, 0.88)). 164 
The reported duration of LNG-IUS use varied from less than 1 year to 14 years, with the latter value 165 
corresponding to the time difference between the introduction of the LNG-IUS in 1994 in Norway and 166 
the date of the last questionnaire (2008). There were 18 cases of ovarian cancer among ever users of 167 
LNG-IUS; 14 of these cases occurred in women who had been using LNG-IUS for less than 7 years, and 3 168 
in women who did not report duration of use. Due to the low number of cases, duration-response 169 
estimates were not calculated.  170 
 The largest risk reduction was observed for endometrial cancer, with a multivariable RR of 0.22 171 
(95% CI: 0.13, 0.40) among ever users compared to never users of LNG-IUS. The final model for 172 
endometrial cancer adjusted for age at start of follow-up, BMI, physical activity level, OC use, parity, and 173 
menopausal status at start of follow-up. The stratified analysis showed that among ever users of OCs, 174 
ever users of LNG-IUS had a RR of endometrial cancer of 0.34 (95% CI: 0.18, 0.65) compared to never 175 
users of LNG-IUS. Among never users of OC, ever users of LNG-IUS had a RR of 0.08 (95% CI: 0.02, 0.34 176 
compared to never users of LNG-IUS. However, these estimates were not significantly different 177 
(pheterogeneity = 0.18). 178 
For breast cancer, both the age-adjusted and the final adjusted model, which included age at start of 179 
follow-up, BMI, physical activity level, maternal history of breast cancer, OC use, and menopausal status 180 
at start of follow-up, showed no association with LNG-IUS use. The incidence rate of breast cancer was 181 
275.7 per 100 000 PY among ever users of LNG-IUS and 281.6 per 100 000 PY among never users. The 182 
multivariable-adjusted RR of breast cancer among ever users of LNG-IUS was 1.03 (95% CI: 0.91, 1.17).  183 
Compared to never users, current users of LNG-IUS had a multivariable RR of breast cancer of 0.97 184 
(95% CI: 0.80, 1.19) and former users a RR of 0.79 (95% CI: 0.64, 0.98). Stratified by duration, ever users 185 
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with up to 5 years of use had a multivariable RR of 1.06 (95% CI: 0.91, 1.24) compared to never users. 186 
Those with more than 5 years of use had a RR of 0.88 (95% CI: 0.68, 1.16). Among ever users of LNG-IUS 187 
with breast cancer, mean time since LNG-IUS cessation was 7.5 (SD 4.4) years (n=237). For ever users of 188 
LNG-IUS not diagnosed with cancer, mean time since cessation of use was 12.5 (SD 3.3) years. 189 
When all cancers were added together to produce an estimate of the total effect of LNG-IUS use, in 190 
ever users the RR of any hormone-related cancer was 0.86 (95% CI: 0.77, 0.97) compared to never users.  191 
 192 




In this population-based prospective cohort study, women who reported ever use of LNG-IUS showed a 195 
strongly reduced risk of both ovarian and endometrial cancer compared to those who did not. LNG-IUS 196 
use was not associated with an increased risk of breast cancer.  197 
 198 
Levonorgestrel and risk of ovarian cancer  199 
Several studies have investigated the association between the use of intrauterine devices and 200 
ovarian cancer, but most did not include LNG-IUS users, save one American, population-based, case-201 
control study, which consisted of 104 cases and 299 controls. This study included 14 LNG-IUS users, and 202 
found a negative association between ever use of intrauterine device and ovarian cancer. When 203 
analyzed by duration, only 4 or fewer years of use was protective (19). A Chinese prospective cohort 204 
study that may have included LNG-IUS users found no association (20).  205 
Two prospective cohort studies by Soini et al. described the association between LNG-IUS use and 206 
ovarian cancer (12, 13). The most recent study (12) was based on 77 ovarian cancer cases occurring in a 207 
cohort of 93 843 women who had been prescribed LNG-IUS for menorrhagia. The study did not adjust 208 
for risk factors, and reported that the age-adjusted SIR of ovarian cancer among women with up to 5 209 
years of LNG-IUS use was 0.59 (95% CI: 0.47, 0.73). Longer duration of use did not decrease the risk 210 
much further. When the entire follow-up period was taken into account, the SIR was 0.49 (95% CI: 0.24, 211 
0.87) for mucinous, 0.55 (95% CI: 0.28, 0.98) for endometrioid, and 0.75 (95% CI: 0.55, 0.99) for serous 212 
ovarian carcinoma. After adjusting for important risk factors, our findings confirm those of Soini et al., 213 
and although our sample size did not permit analyses on histological subtypes, our adjusted results 214 
strengthen the evidence of a causal association between LNG-IUS and decreased risk of ovarian cancer.  215 
It is generally assumed that combined OCs prevent ovarian cancer by inhibiting ovulation (21) and 216 
possibly by reducing menstrual bleeding (22). Sparse menstruations lead to less retrograde 217 
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menstruation, which, by implanting as endometriosis, is thought to be a source of either endometrioid 218 
carcinoma, clear cell carcinoma, or possibly low-grade serous carcinoma (23). By other mechanisms, 219 
retrograde menstruation and follicular fluid released during ovulation may induce serous tubal 220 
intraepithelial carcinoma (22), which potentially could enter the ruptured ovarian epithelium and, 221 
stimulated by the hormone-rich milieu of the ovary, cause high-grade serous carcinoma (24).  222 
Levonorgestrel is a potent progestin. LNG-IUS used in Norway at the time questionnaires were 223 
completed initially release 20 µg LNG per day, decreasing to 11 µg/day for an average of 14 µg/day over 224 
a five-year period (25). LNG-IUS exerts its contraceptive effect by suppressing the endometrium, 225 
thickening the cervical mucus, and, partly, by inhibiting ovulation through the hypothalamic-pituitary 226 
axis (26). Most LNG-IUS users have light menstruations and 20-50% become amenorrheic (27). In the 227 
present study, 30% of LNG-IUS users had unknown menopausal status, compared to 5% of non-users. In 228 
an ultrasound study of 22 women, of which one-third were amenorrheic after 7 or more years of LNG-229 
IUS use, approximately 30% of amenorrheic women and 60% of still menstruating women had ovulatory 230 
cycles with follicular rupture (26).  231 
Risch (28) argued that, since the protective effect of progestin-only contraceptives, which do not 232 
completely suppress ovulation, is comparable to the effect of combined OCs on ovarian cancer, 233 
progestogens likely have a direct anti-tumorigenic effect on ovarian cancer. Such a concept was 234 
supported by Merritt et al. (29) notably with regard to high natural progesterone levels during 235 
pregnancy, though the effects of natural progesterone and those of synthetic progestins are not 236 
superimposable. The LNG-IUS alleviates symptoms  of endometriosis, and Lockhat et al. (30) showed 237 
that in addition to the vascular delivery of levonorgestrel to endometriotic implants, direct contact with 238 
levonorgestrel in peritoneal fluid (transferred to this fluid via blood, not by diffusion from the uterine 239 
cavity) likely plays a significant role. A similar direct effect on ovarian tumors or tumor precursor cells is 240 
also possible (31). This hypothesis, however, does not correspond with a Danish population-based case-241 
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control study (21) nor with a previous study from the NOWAC cohort (32), both of which found that only 242 
use of combined OCs, not oral progestogens alone, prevents ovarian cancer. Faber et al. (21) concluded 243 
that OCs prevent ovarian cancer through the inhibition of ovulation. It is plausible that the preventive 244 
effect of LNG-IUS on ovarian cancer works through partial inhibition of both ovulation and 245 
menstruation. 246 
 247 
Levonorgestrel and risk of endometrial cancer  248 
Our adjusted results also confirm the observations of Soini et al. (13) for endometrial cancer. That 249 
study adjusted for smoking, diet and alcohol consumption, socioeconomic status, and physical activity, 250 
and reported a SIR of endometrial cancer of 0.46 (95% CI: 0.33, 0.64) in LNG-IUS users compared to the 251 
general population. In a pooled analysis of four cohort and 14 case-control studies, Felix et al. (33) 252 
calculated the association between use of different intrauterine devices and the risk of endometrial 253 
cancer and found no association with LNG-IUS. However, due to the low number of women in the LNG-254 
IUS exposure group, they disregarded this result and called for further studies.  255 
 256 
The anti-proliferative effect of LNG-IUS is superior to that of oral progestins in the treatment of 257 
endometrial hyperplasia (15), and a protective effect of this device on endometrial cancer in the general 258 
population is to be expected. Our results indicate the size of the risk reduction in a cohort 259 
representative of the general population. Since the proportion of ever users of OCs was significantly 260 
different among ever and never users of LNG-IUS, we performed an analysis stratified by ever OC use. 261 
The difference was non-significant, but suggestive of a stronger protective effect of LNG-IUS among 262 




Levonorgestrel and risk of breast cancer  265 
Contrary to Soini et al. (14), we did not observe an increased risk of breast cancer among LNG-IUS 266 
users. Soini et al. (14) reported a clear increased risk of certain types of breast cancer, but did not 267 
present SIRs of total breast cancer. In the earlier study by Soini et al. (13), the SIR of total breast cancer 268 
was 1.19 (95% CI: 1.13, 1.25). In all three studies by Soini et al. (12-14) follow-up ended at age 55 years. 269 
The discrepancy between our findings and those of Soini et al. (14) could be due to their lack of 270 
adjustment, although adjustment had little effect on our estimates.  271 
In a recent nested case-control study of women in the Norwegian breast cancer screening program 272 
(aged 50-69 years), Ellingjord-Dale et al. (34) did not find an association between duration of IUD use 273 
and overall risk of breast cancer by duration of use (in intervals), although there was a statistically 274 
significant trend. The results indicated increased and decreased risks of different breast cancer 275 
subtypes. This study did not differentiate between types of intrauterine devices, but assuming a 276 
population-representative sample and data collected from 2006 onwards, LNG-IUS users constituted a 277 
large fraction of intrauterine device users (11). When we stratified on duration of use (up to 5 and more 278 
than 5 years), we observed no association with breast cancer in either stratum. We did not study breast 279 
cancer subtypes, and we did not test for trend.  280 
A recent prospective cohort study showed that current and recent users of LNG-IUS had an 281 
increased risk of breast cancer compared to never users of hormonal contraceptives (RR 1.21; 95% CI: 282 
1.11, 1.33). This study included all women aged 15-49 in Denmark, and adjusted for age, calendar year, 283 
education, polycystic ovary syndrome, endometriosis, parity, and family history of premenopausal 284 
cancer of the breast or ovary. Our null finding remained when we restricted the analyses to current 285 
users of LNG-IUS. However, in our study, few participants were younger than 46 years. Moreover, the 286 
mean duration of LNG-IUS use was 4 years, and average time since cessation of use was 7.5 years. When 287 
Mørch et al stratified by duration of use and time since cessation, women in the corresponding category 288 
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did not have increased and risk of breast cancer. Mørch et al. found that more than 5 years of use was 289 
associated with increased cancer risk, and the risk lasted up to 10 years after cessation of use (9). In our 290 
analysis stratified on duration we could not reproduce this finding. 291 
Among previous studies, a Finnish case-control study of 9537 breast cancer cases and 21 598 292 
controls adjusted for age at menarche, smoking, alcohol use, BMI, and family history of breast cancer 293 
and found a positive association between ever use of LNG-IUS and breast cancer in postmenopausal 294 
women (aged 51-64), while for premenopausal women no association was observed (35). The authors 295 
mentioned the possible presence of selection bias, as some practitioners, at least in Finland (this is also 296 
the case in Norway), have regarded the LNG-IUS as a preferable option for women with an increased risk 297 
of breast cancer.  298 
 299 
Strengths and limitations 300 
Strengths of this study include its prospective design, inclusion of lifestyle information, and a population 301 
based study cohort with women who were likely using the LNG-IUS for both contraceptive and medical 302 
reasons. BMI and OCs were validated by test-retest in a subset of participants (Skeie 2015, Lund, 303 
Dumeaux et al. 2008), and physical activity and menopausal status by measurements (Borch 304 
2012,Waaseth 2008). Number of children was validated by Lund, Kumle (17). The LNG-IUS variable was 305 
not validated, nor was maternal history of breast cancer and age at menarche. Compared to non-306 
responders, responders were at a disadvantage with regard to some risk factors for the cancers in this 307 
study (lower age at menarche and nulliparity), but also had favorable characteristics (proportion of ever 308 
OC users and maternal history of breast cancer). We included OC use as a dichotomous variable, as 309 
analyzing OC use by duration did not change the estimate of the main exposure. We did not adjust for 310 
time since OC use. Insufficient adjustment for this, and for use of other hormonal contraceptives, may 311 
have caused residual confounding in our estimates. 312 
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The use of cancer registry data ensured near complete follow-up of cancer cases. However, due to 313 
the strong protective effect of LNG-IUS, the study had a limited number of ovarian and endometrial 314 
cancer cases. We were not able to calculate specific rates by subtype, nor could we analyze duration 315 
effects on these cancer types. 316 
The mean age at enrollment was lower among ever users of LNG-IUS than never users. The 317 
gynecological practice of removing or leaving LNG-IUS in place at the time of menopause, varies; 318 
nevertheless, even if left in place, its protective effect, if any, could be transitory, potentially delaying 319 
the "natural" appearance of ovarian cancer. We created a Lexis diagram of the distribution of ovarian 320 
cancer incidence in both ever users and never users of LNG-IUS, which showed a lower, but parallel 321 
incidence rate among all LNG-IUS users aged less than 65 years, and a decreased incidence rate among 322 
those aged 65 years or over, as compared to never users. However, among ever users of LNG-IUS, there 323 
was one case that occurred after age 64 years, which introduces uncertainty into the estimation.  324 
This is one of the few epidemiological studies that presents data specifically on LNG-IUS use, with 325 
estimates generalizable to the general female population of Norway. However, we used self-reported 326 
exposure data, which introduces a risk of misclassification. Considering the prescription routines, it is 327 
likely that women were counselled by their physician and required to make a choice, and thus were 328 
aware of which type of intrauterine device they were using. Nevertheless, we excluded women who 329 
indicated using LNG-IUS before it was on the market.  330 
CONCLUSION 331 
This study shows that a relatively short period of LNG-IUS use is associated with an almost halved risk of 332 
ovarian cancer, while the risk of breast cancer remains unchanged. Our results are in agreement with 333 
existing data, and show a negative association in a cohort of women where the majority was older than 334 
in previous studies. Although these findings suggest that LNG-IUS should be considered for inclusion in 335 
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the ovarian cancer prevention strategy for normal-risk women in addition to OCs (36), an updated meta-336 
analysis of the effect of LNG-IUS on breast cancer is needed before firm conclusions can be drawn.  337 
 338 
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Table 1 Characteristics of ever users (N=9144) and never users (N=95 174) of the levonorgestrel-
releasing intrauterine system (LNG-IUS) in the Norwegian Women and Cancer Study, 1998-2015 
* P-value from a chi-square test of independence, excluding missing value 
 
Characteristics  LNG-IUS  
  Ever users Never users p-value* 














 46-50 3855 42 % 21581 23 %  
 51-55 3051 33 % 30526 32 %  
 56-60 795 9 % 18589 20 %  
 61-65 145 2 % 7811 8 %  
 66-70 20 <1 % 3012 3 %  
 71-76 7 <1 % 2478 3 %  
Body mass index (kg/m2) <25 5295 58 % 54133 57 % 0.18 
 ≥25 3637 40 % 38306 40 %  
 missing 212  2735   
Physical activity level very low 248 3 % 3506 4 % <0.01 
 Low 1518 17 % 18200 19 %  
 intermediate 3479 38 % 36971 39 %  
 High 2972 33 % 23871 25 %  
 very high 556 6 % 4796 5 %  
 missing 371  7830   
Maternal history of breast 
cancer 
Yes 478 5 % 5032 5 % 0.80 
Age at menarche (years) <12 811 9 % 8428 9 % 0.01 
 12-14 6646 73 % 67897 71 %  
 ≥15 1543 17 % 17364 18 %  
 missing 144  1485   
       
Ever use of oral 
contraceptives 
Yes 6476 71 % 52259 55 % <0.01 
Parity None 307 3 % 9231 10 % <0.01 
 1-2 5502 60 % 49935 52 %  
 3-4 3173 35 % 32762 34 %  
 ≥5 162 2 % 3246 3 %  














 Peri 1206 13 % 8533 9 %  
 Post 3060 33 % 57128 60 %  
 Unknown 2753 30 % 5190 5 %  
Table 2 Site-specific cancer incidence rates and relative risks comparing ever users (person-years [PY] =107 701) and never users (PY=1 197 734) 
of the levonorgestrel-releasing intrauterine system (LNG-IUS) in the Norwegian Women and Cancer Study  
Cancer type LNG-IUS user 
status 
Cancer cases Incidence rate per  




RR (95% CI) 




16.7 (9.9, 26.4) 
38.1 (34.7, 41.8) 
0.49 (0.30, 0.82) 0.53 (0.32, 0.88)a 




13.9 (7.8, 23.0) 
70.0 (65.4, 74.9) 
0.19 (0.11, 0.40) 0.22 (0.13, 0.40)b 




275.7 (245.3, 309.0) 
281.6 (272.2, 291.3) 
1.02 (0.90, 1.15) 1.03 (0.91, 1.17)c 






306.4 (274.2, 341.3)  
389.7 (378.7, 401.2)  
0.84 (0.74, 0.94) 0.86 (0.77, 0.97)d 
a Adjusted for OC use, age at start of follow-up, menopausal status at start of follow-up, parity 
b Adjusted for OC use, age at start of follow-up, menopause status at start of follow-up, BMI, physical activity, parity 
c Adjusted for OC use, age at start of follow-up, maternal history of breast cancer, BMI, physical activity, menopause status at start of follow-up 
d Adjusted for OC use, age at start of follow-up, maternal history of breast cancer, BMI, physical activity, menopause status at start of follow-up, parity 
 





Supplementary table 1 Selected characteristics of responders and non-responders to the question ‘Have 
you ever used a hormone intrauterine device (IUD)?’ in the Norwegian Women and Cancer Study, 1998-
2015 
 
* P-value from a chi-square test of independence, excluding missing value 
 





15 442 p-value* 
Maternal history of breast 
cancer 
Yes 5515 5 % 940 6 % <.001 
Age at menarche (years) <12 9246  9 % 1318 8 % <.001 
 12-14 74584 71 % 10767 70 %  
 ≥15 18920 18 % 3030 20 %  
 missing 1630 2 % 327 2 %  
       
Ever use of oral 
contraceptives 
Yes 58761 56 % 8366 54 % <.001 
Parity None 9547 9 % 939 6 % <.001 
 1-2 55466 53 % 8546 55 %  
 3-4 35957 35% 5535 36 %  
 ≥5 3410 3 % 422 3 %  
